The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) is associated with robust antitumor activity. Ribociclib (LEE011) is an orally bioavailable CDK4/6 inhibitor that is approved for the treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sunkyu, Tiedt, Ralph, Loo, Alice, Horn, Thomas, Delach, Scott, Kovats, Steven, Haas, Kristy, Engstler, Barbara Schacher, Cao, Alexander, Pinzon-Ortiz, Maria, Mulford, Iain, Acker, Michael G., Chopra, Rajiv, Brain, Christopher, di Tomaso, Emmanuelle, Sellers, William R., Caponigro, Giordano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219668/
https://www.ncbi.nlm.nih.gov/pubmed/30443290
http://dx.doi.org/10.18632/oncotarget.26215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219668/
https://www.ncbi.nlm.nih.gov/pubmed/30443290
http://dx.doi.org/10.18632/oncotarget.26215

Ejemplares similares